ストックスクリーナーアプリを入手
2.93
1.68%
-0.05
アフターアワーズ：
2.99
0.06
+2.05%
前日終値:
$2.98
開ける：
$2.96
24時間の取引高:
196.89K
Relative Volume:
0.71
時価総額：
$196.73M
収益：
$7.69M
当期純損益:
$-17.65M
株価収益率:
-7.8279
EPS:
-0.3743
ネットキャッシュフロー:
$-15.72M
1週間 パフォーマンス:
-11.48%
1か月 パフォーマンス:
-23.30%
6か月 パフォーマンス:
-28.01%
1年 パフォーマンス:
+45.05%
1日の値動き範囲:
$2.87
$3.185
1週間の範囲:
$2.81
$3.35
52週間の値動き範囲:
$1.30
$4.85
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
2.93 | 196.73M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Guggenheim | Buy |
| 2025-08-06 | 開始されました | Leerink Partners | Outperform |
| 2025-01-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | 開始されました | China Renaissance | Buy |
| 2021-03-08 | 開始されました | Goldman | Buy |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Adagene Inc Adr (ADAG) 最新ニュース
Form 4 Adagene Inc. For: 25 September By Investing.com - Investing.com Nigeria
Form 4 Adagene Inc. For: 25 September - Investing.com India
A $3-a-share purchase leaves Adagene (ADAG) finance chief Tam Man Kin holding 12,000 depositary shares. - Stock Titan
Adagene Announces Finance Executive Resignation Effective September 30, 2026 - TipRanks
A finance director’s resignation takes effect Sept. 30 at Adagene (ADAG). - Stock Titan
ADAG Stock Price, Quote & Chart - ChartMill
Adagene (NASDAQ: ADAG) Obtains NMPA IND Approval for ADG138 Phase 1 Trial in Advanced Solid Tumors - Kalkine Media
China approves Adagene’s IND application for ADG138 cancer drug - Investing.com
China greenlights Adagene (NASDAQ: ADAG) cancer drug for first human trial - Stock Titan
Adagene Announces NMPA Clearance of Investigational New - GlobeNewswire
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know - Eastern Progress
Adagene Stock Price Forecast. Should You Buy ADAG? - StockInvest.us
Co- Founder of Adagene Peter P. Luo Buys 30% More Shares - simplywall.st
H.C. Wainwright reiterates Adagene stock rating on milestone payments - Investing.com
Adagene, Third Arc Bio expand partnership with first lead selection - investing.com
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - The Manila Times
Cancer partner will fund new trials in Adagene (ADAG) collaboration - Stock Titan
Adagene Secures Milestone Payments in Exelixis SAFEbody ADC Collaboration - TipRanks
Cancer drug milestone brings new cash to Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - Yahoo! Finance Canada
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Barchart.com
Adagene (NASDAQ: ADAG) officer to sell 131K ADS to cover option taxes - Stock Titan
Adagene to Participate in Three Upcoming Investor Conferences - GlobeNewswire
Adagene (NASDAQ: ADAG) officer plans August ADS sell-to-cover - Stock Titan
Adagene (ADAG): WuXi PharmaTech and WuXi AppTec disclose 3.5% beneficial stake - Stock Titan
Adagene Inc. (Nasdaq: ADAG) boosts cash to US$127.9M and updates H1 2026 results - Stock Titan
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
Adagene (NASDAQ:ADAG) CEO Peter Luo Acquires 22,966 Shares - MarketBeat
Exome Asset Management LLC Decreases Holdings in Adagene Inc. Sponsored ADR $ADAG - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Adagene (ADAG) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Guggenheim reiterates Adagene stock Buy rating on competitor shift - Investing.com
Adagene (ADAG) Stifel 2026 Targeted Oncology Virtual Forum Summary - Quartr
Adagene Discloses Preliminary US$127.9 Million Cash Balance as of June 30, 2026 - The Globe and Mail
Adagene (ADAG) reports preliminary US$127.9M cash balance in June 2026 6-K - Stock Titan
ADAG - Finviz
Adagene, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:ADAG) - TradingView
Adagene (ADAG) upgraded to buy: Here's what you should know - MSN
Adagene (NASDAQ: ADAG) Schedule 13D/A details Luo group and trust stakes - Stock Titan
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Are medical stocks lagging Adagene (ADAG) this year? - MSN
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene spotlights ADG126 strategy as masked CTLA-4 trial advances in colorectal cancer - MSN
Adagene Inc. (ADAG) Presses Lower: Support Test in Sight After 1.88% DeclineTriple EMA - dars.gov.et
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - sharewise.com
WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Inc. to Participate in Stifel Annual Virtual Oncology Event and Jefferies Global Healthcare Conference - Quiver Quantitative
Adagene to Participate in Two Upcoming Investor Conferences - marketscreener.com
Janus Henderson (ADAG) reports 6.67M ADRs, 10.1% stake (04/30/2026) - Stock Titan
Adagene Inc Adr (ADAG) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):